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In the failing heart, NADPH oxidase and uncoupled NO synthase utilize cytosolic NADPH to form superoxide. NADPH is supplied principally
by the pentose phosphate pathway, whose rate-limiting enzyme is glucose 6-phosphate dehydrogenase (G6PD). Therefore, we hypothesized that
cardiac G6PD activation drives part of the excessive superoxide production implicated in the pathogenesis of heart failure. Pacing-induced heart
failure was performed in eight chronically instrumented dogs. Seven normal dogs served as control. End-stage failure occurred after 28 ± 1 days
of pacing, when left ventricular end-diastolic pressure reached 25 mm Hg. In left ventricular tissue homogenates, spontaneous superoxide
generation measured by lucigenin (5 μM) chemiluminescence was markedly increased in heart failure (1338 ± 419 vs. 419 ± 102 AU/mg protein,
P < 0.05), as were NADPH levels (15.4 ± 1.5 vs. 7.5 ± 1.5 μmol/gww, P < 0.05). Superoxide production was further stimulated by the addition of
NADPH. The NADPH oxidase inhibitor gp91ds-tat (50 μM) and the NO synthase inhibitor L-NAME (1 mM) both significantly lowered superoxide
generation in failing heart homogenates by 80% and 76%, respectively. G6PD was upregulated and its activity higher in heart failure compared to
control (0.61 ± 0.10 vs. 0.24 ± 0.03 nmol/min/mg protein, P < 0.05), while superoxide production decreased to normal levels in the presence of
the G6PD inhibitor 6-aminonicotinamide. We conclude that the activation of myocardial G6PD is a novel mechanism that enhances NADPH
availability and fuels superoxide-generating enzymes in heart failure.
© 2006 Elsevier Inc. All rights reserved.Keywords: Heart failure; NADPH oxidase; Glucose-6-phosphate; Pentose phosphate pathway1. Introduction
Excessive production of reactive oxygen species (ROS) is
implicated in the pathogenesis of several cardiovascular
diseases, including heart failure [1]. A large number of clinical
and experimental studies have shown increased oxidative stress
in the failing heart, with detrimental consequences that range
from endothelial dysfunction to contractile impairment and
ventricular remodeling [2]. The main sources of superoxide
anion (O2
−), a major precursor of reactive oxygen species,⁎ Corresponding author. Fax: +1 914 594 4018.
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doi:10.1016/j.yjmcc.2006.05.003include the mitochondrial respiratory chain [3], xanthine
oxidase [4], and NADPH oxidase [5]. The relative contribution
of these enzymes to O2
− production in the failing heart is not well
defined, yet. Recent studies have suggested important roles for
both xanthine oxidase [6], and NADPH oxidase as sources of
cardiac O2
− in heart failure patients [7,8]. The latter enzyme
utilizes both cytosolic NADPH or NADH as donors of reducing
equivalents to transfer one electron to molecular oxygen,
thereby producing O2
−. The increased activity of NADPH
oxidase in response to mediators such as angiotensin II,
norepinephrine, and TNFα is presently recognized as a chief
mechanism of vascular disease [9], but its potential impact on
oxidative stress of the failing myocardium requires further
elucidation. In addition, when constitutive NO synthase is
341S.A. Gupte et al. / Journal of Molecular and Cellular Cardiology 41 (2006) 340–349uncoupled from essential cofactors, as found in the failing heart,
it transfers electrons from NADPH to oxygen, thus becoming an
additional source of O2
− [10].
The generation of O2
− from NADPH oxidase and uncoupled
NO synthase depends not only on enzyme activation, but also
on the availability of reducing equivalents. It is conceivable,
therefore, that, in the presence of hyperactive NADPH oxidase
and uncoupled NO synthase, alterations of the metabolic
pathways accounting for NAD+ and NADP+ reduction can
potentially affect the rate of O2
− production. Other investigators
and we have previously reported profound alterations of fatty
acid and carbohydrate metabolism in the failing heart [11]. In
particular, myocardial glucose uptake and oxidation are
increased [12,13], although the glycolytic pathway and the
mitochondrial capacity to oxidize carbohydrates appear down-
regulated, as opposed to upregulated [14,15]. A small fraction
of total glucose in the cytosol can also be oxidized to ribose by
the pentose phosphate pathway. Moreover, it has been
previously shown by us and others that NADPH oxidase
preferentially utilizes NADPH derived from the pentose
phosphate pathway [16,17]. In the light of these findings, we
hypothesized that, in the failing heart, more glucose is oxidized
through the pentose phosphate pathway, with a consequent
increase in electron donors available to fuel O2
− generating
enzymes. This hypothesis was tested in myocardial tissue
harvested from dogs with pacing-induced heart failure, an
established model of dilated cardiomyopathy.
2. Methods
2.1. Surgical instrumentation and in vivo protocol
Fifteen dogs were chronically instrumented and heart
failure was induced in eight by pacing the left ventricle at
210 beats/min for 3 weeks and at 240 beats/min thereafter. The
remaining seven dogs were used as a control. Hemodynamics
recordings and two-dimensional and M-mode echocardiogra-
phy were performed at baseline and during terminal
decompensation. Dogs were considered in end-stage heart
failure when left ventricular end-diastolic pressure reached
25 mm Hg and clinical signs of severe decompensation were
observed. At this point, the dogs were anesthetized with
30 mg/kg i.v. of sodium pentobarbital to harvest and snap-
freeze left ventricular tissue samples. These methods have
been fully described by us [18] and the protocol was approved
by the Institutional Animal Care and Use Committee of the
New York Medical College.
2.2. Cardiac tissue
Left ventricular tissue was pulverized in liquid nitrogen and
homogenates were prepared in MOPS (50 mmol/l)-Sucrose
(250 mmol/l) buffer at pH 7.4, as previously described [17,19].
Only freshly prepared homogenates were used for biochemical
assays.
To identify the source of O2
−, the homogenates were brought
to a final volume of 50 μl and pretreated for 30 min with: (1) thexanthine oxidase inhibitors allopurinol (100 μmol/l) [20] and
oxypurinol (100 μmol/l) [21]; (2) the cofactor tetrahydrobiop-
terin (10 μmol/l) [22], and the inhibitor L-NAME (1 mmol/l)
[10] to prevent O2
− generation from NO synthase; (3) the
specific NADPH oxidase inhibitor gp91ds-tat (50 μmol/l) [23];
(4) 6-aminonicotinamide (5 mmol/l), an inhibitor of glucose-6-
phosphate dehydrogenase [17,24]. Time-matched control
samples were incubated for 30 minutes at 37 °C without adding
any drug. Incubated samples (20 μl) were placed in plastic
scintillation minivials containing 5 μM lucigenin for the
detection of O2
− in a final volume of 1 ml of air-equilibrated
Krebs solution buffered with 10 mmol/l HEPES-NaOH (pH
7.4), as previously described [17]. In a separate set of
experiments, lucigenin chemiluminescence was measured
from normal and heart failure homogenate samples without
and with NADPH (50-μmol/l). Lucigenin assays were done in
the presence and absence of O2
− scavenger, superoxide
dismutase (SOD).
2.3. Hydrogen peroxide and peroxynitrite production
Hydrogen peroxide levels were measured by chemilumines-
cence methods as previously described [25]. Briefly, hydrogen
peroxide was estimated by incubating homogenate samples
(10 μl) in luminol (10 μmol/l) and horseradish peroxidase
(100 nmol/l) with and without catalase (200 U/ml), and luminol
chemiluminescence was measured. To measure peroxynitrite
production, tissue homogenate samples (10 μl) were incubated
in luminol (100 μmol/l) and luminol chemiluminesence was
used after a brief modification as previously described [26].
Luminol assays were done in the presence and absence of H2O2
scavenger, catalase.
2.4. Glutathione concentration and glutathione reductase
activity
Frozen samples were homogenized in 50 mmol/l potassium
phosphate buffer, pH 6–7, 1 mmol/l EDTA and then centrifuged
at 10,000 × g for 15 min at 4 °C. The supernatant was used for
measurement of oxidized glutathione (GSSG) after deproteinat-
ing the sample with equal amounts of 5 g/50 ml metaphosphoric
acid. The samples were centrifuged at 2000 × g for at least
2 min, and the supernatant was used for GSSG measurement
after neutralization with 4 mol/l triethanolamine. After
separation by centrifugation and neutralization, the samples
were treated with 1 mol/l 2-vinylpyridine. GSSG concentration
was measured using a commercially available assay kit
(Cayman Chemical) [27]. Also, glutathione reductase activity
in myocardial homogenates was determined by a commercially
available kit (Cayman Chemical).
2.5. Superoxide dismutase activity
We measured superoxide dismutase (SOD) activity as an
indicator of oxidative stress induced by O2
− [28]. Cardiac tissue
homogenates was assayed with a commercially available kit
(Cayman Chemicals).
342 S.A. Gupte et al. / Journal of Molecular and Cellular Cardiology 41 (2006) 340–3492.6. Lipid peroxidation
Malondialdehyde and 4-hydroxyalkenals, end products of
peroxidation of polyunsaturated fatty acids with related esters,
were measured in cardiac tissue extract with a colorimetric
method by employing a commercially available assay kit
(Calbiochem) [18].
2.7. Oxidized and reduced pyridine nucleotide concentrations
NADPH was determined by HPLC using previously
described methods [17]. Briefly, to measure NADPH, frozen
tissues were homogenized in an extraction medium containing
NaOH (0.02 N) and cysteine (0.5 mmol/l) at 0 °C. The extracts
then were heated at 60 °C for 10 min and neutralized with 2 ml
of 0.25 M glycylglycine buffer, pH 7.6. The neutralized
extracts were centrifuged at 10,000×g for 10 min, the
supernatants were passed through 0.45 μm Millipore filters,
and the filtered solutions were used to measure NADPH by
HPLC. NADPH were eluted from a reverse-phase HPLC
column (4.6× 250 mm; Supelco C18, Sigma) at room
temperature using HP 1100 Series (Agilent Technologies,
DE) with a buffer system consisting of 100 mmol/l potassium
phosphate (pH 6.0) (buffer A), and 100 mmol/l potassium
phosphate (pH 6.0) containing 5% methanol (buffer B). The
column was eluted with 100% buffer A from 0 to 8.5 min, 80%
buffer A plus 20% buffer B from 8.5 to 14.5 min, and 100%
buffer B from 14.5 to 40 min. The flow rate was 1.0 ml/min,
and the ultraviolet absorbance was monitored at 260 nm.
NADPH standards were used to calibrate the HPLC. Internal
standards containing 2 nmol of NADPH, NADH, NADP+, and
NAD+ were used to verify the quantitative recovery of the
extraction procedure and HPLC retention time in the presence
and absence of tissue samples.
2.8. Glucose-6-phosphate dehydrogenase activity
The activity glucose-6-phosphate dehydrogenase (G6PD),
the rate limiting enzyme in the pentose phosphate pathway,
was measured in myocardial tissue homogenates by following
the reduction of NADP+ to NADPH [17]. NADPH fluores-
cence was detected at 340 nm (Ex) and 460 nm (Em) using a
Flx800 microplate fluorescence detector, BioTek Instruments,
Winooski, Vermont, USA.Table 1
Primer and probe sequences used in real time quantitative RT-PCR
Gene Primer/Probe Se
g6pd Forward 5′
Reverse 5′
Probe 5′
nox2 Forward 5′
Reverse 5′
Probe 5′
nox4 Forward 5′
Reverse 5′
Probe 5′2.9. 6-Phosphogluconate concentration
6-Phosphogluconate, a product of the oxidative branch of the
pentose phosphate pathway, was measured in myocardial tissue
by the method of Kauffman et al. [29]. The reduction of NADP+
(0.02 mmol/l) to NADPH was catalyzed by 6-phosphogluco-
nate dehydrogenase (0.5 μg/ml) at 37 °C for 20 min in Tris–HCl
(0.05 mol/l) buffer (pH 8.0) containing EDTA (0.1 mmol/l),
dithiothreitol (0.1 mmol/l), and ammonium acetate (0.03 mol/l).
NADPH concentration was then detected fluorometrically as
previously described by us [17].
2.10. Real-time polymerase chain reaction
The expression of selected genes was quantitated by real-
time quantitative polymerase chain reaction (PCR) as described
previously [18]. Analysis was focused on G6PD and the
NADPH subunits Nox-2 and Nox-4, while the traditional
housekeeping gene ribosomal 18 S was used for normalization.
We chose to measure Nox-4 and Nox-2 expression, since both
these oxidases are expressed in vascular and myocardial tissue
[7,17]. Specific quantitative assays were designed from dog
sequences available in GenBank, except in the cases of Nox-2
and Nox-4 for which the dog sequences were not available. In
contrast, these genes have been cloned for the human, mouse,
and rat. Multiple assays were then designed using the human
sequence for these genes, in a region that was highly conserved
between the three species. These human-specific assays were
subsequently tested for compatibility in the dog. Primers and
probes were designed to be isoform specific, spanning sites
where two exons join (splice sites) when such sites are known
(preventing recognition of the assay to any potential contam-
inating genomic DNA). Sequences of these primers and probes
are given in Table 1. Standard RNAwas made for all assays by
the T7 polymerase method (Ambion), using total RNA isolated
from the dog heart. Transcript levels are expressed as the number
of molecules of mRNA per nanogram of total RNA (as
measured by UV spectrophotometry).
2.11. Western immunoblot analysis
Protein was extracted from frozen tissue as previously
described [17] and its concentration measured spectrophoto-
metrically with a colorimetric assay (Bio-Rad DC reagent).quence
-GACCACTACCTGGGCAAGG-3′
-CGATGTTGTCTCGGTTCCA-3′
-FAM-ATCCTGTTGGCAAACCTCAGCACCAT-TAMRA-3′
-AGCCAGATGCAGGAAAGGA-3′
-TCATCATGGTGCACAGCAAA-3′
-FAM-ATTGGCCTGAGACTCATCCCAGCCA-TAMRA-3′
-CGTCCTCGGTGGAAACTTTT-3′
-GTGAATTGGGTCCACAACAGA-3′
-FAM-CACCAACTGTTTTTCCTCTGTTATATTTTGCTATTTCA-TAMRA-3′
Table 2
Hemodynamics and echocardiographic parameters at control and in end-stage
heart failure
Control (n = 7) Heart failure (n = 8)
LVEDP (mm Hg) 6 ± 1.0 25 ± 1.5 ⁎
LVSP (mm Hg) 127 ± 3.3 96 ± 2.8*
dP/dtmax (mm Hg s
− 1) 3048 ± 200 1372 ± 100*
MCBF (ml min− 1) 34.9 ± 3.9 30.2 ± 4.7
LVEDD (mm) 44.3 ± 1.0 52.0 ± 1.5*
LVEF (%) 69 ± 3.6 31.4 ± 2*
LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic
pressure; dP/dtmax, maximum derivative of left ventricular pressure; MCBF,
mean blood flow in the left circumflex coronary artery; LVEDD, left ventricular
end-diastolic diameter; LVEF, left ventricular ejection fraction.
⁎ P < 0.05 vs. control.
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electrophoresis, transferred onto a PVDF membrane, and
incubated with specific antibody against G6PD (1:500
dilution, Sigma Chemical), Nox-2 (1:100 dilution, Transduc-
tion Laboratory), and Nox-4 (1:100 dilution, Santacruz
Biotechnology). After conjugation with the secondary
antibody, the membranes were developed in a chemilumi-
nescence substrate solution (Pierce SuperSignal Chemilumi-
nescence Substrate), and re-probed for calsequestrin [14] to
verify the uniformity of protein loading. Bands were
visualized by autoradiography and quantified using commer-
cially available software. Results are expressed as percentage
of the density of a standard sample loaded on all membranes
in triplicate.
2.12. Coimmunoprecipitation
The activation state of NADPH oxidase was tested by
determining the formation of complexes of Nox bound to the
recruitable subunits of the enzyme [30]. Therefore, we first
tested commercially available antibodies to detect the subunits
p47phox, p67phox, and rac-1 in canine tissue. Unfortunately, we
obtained a good and reproducible signal only with the anti-
p67phox antibody. Frozen samples were homogenized in
20 mM Tris–HCl pH 7.4 buffer, containing 1% NP-40,
0.25% sodium deoxycholate, 100 mM NaCl, 1 mM EGTA,
1 mM PMSF, 1 mM Na3VO4, 1 mM NaF, 1 μg/ml aprotinin,
1 μg/ml leupeptin, and 1 μg/ml pepstatin. After protein
extraction, p67phox was immunoprecipitated using goat
polyclonal antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) bound to IgA and IgG beads (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), after which SDS gel
electrophoresis will be performed. Separated proteins were
blotted onto 0.2 μm nitrocellulose (16 h, 30 V) and
immunostained with anti-Nox-2 antibody (BD Bioscience,
San Diego, CA, USA) followed by incubation with HRP-
labeled appropriate secondary antibodies (Pierce, IL, USA).
Specific proteins were detected by chemiluminescence
(Pierce).
2.13. Statistical analysis
Values are expressed as means ± SEM. Differences
among groups were tested with one-way ANOVA followed
by Bonferroni's post hoc test. The acceptable level of
significance was P < 0.05. Differences were considered
statistically significant at a nominal significance of P <
0.05.
3. Results
3.1. Heart failure
Dogs developed end-stage failure after 28 ± 1 days of
pacing, when left ventricular end-diastolic pressure reached
25 mm Hg. Changes in the main hemodynamic and
echocardiographic parameters are summarized in Table 2.3.2. Superoxide production, superoxide dismutase activity,
hydrogen peroxide generation, and products of lipid
peroxidation
Fig. 1 shows O2
− levels in myocardial tissue from normal
(1A) and failing (1B) hearts detected by lucigenin (5-μmol/l)
chemiluminescence. O2
− was significantly higher in failing
myocardium. In few experiments, O2
− detections were
performed in the absence and presence of NADPH
regenerating system consisting of glucose-6-phosphate
(200 μmol/l) and NADP+ (100 μmol/l) added in each
reaction. Addition of NADPH regenerating system to each
reaction did affect basal O2
− generation. Pretreatment of
normal (n = 7) and heart failure (n = 8) myocardial tissue
with polyethylene glycol-superoxide dismutase (500 U/ml)
and tiron (10 μM) inhibited lucigenin chemiluminescence,
indicating that the signal was specific for O2
−. No
pharmacological agents used in this study, except for
tetrahydrobiopterin and gp91ds-tat, attenuated O2
− signals in
normal myocardium (Fig. 1A). In failing myocardium (Fig.
1B), the O2
−-induced chemiluminescence was not significantly
changed by the xanthine oxidase inhibitors, allopurinol and
oxypurinol, but was attenuated (P < 0.05) by the NO
synthase cofactor tetrahydrobiopterin and inhibitor L-NAME
(50–60%), and by the NADPH oxidase inhibitor gp91ds-tat
(80–90%). A scrambled analogue of gp91ds-tat did not exert
any effect on O2
− and H2O2 production in normal and heart
failure myocardial homogenates.
Furthermore, we measured SOD activity as an indirect
indicator of oxidative stress [28] induced by elevated O2
− levels
in normal and heart failure myocardial homogenates. As shown
in Fig. 1C, SOD activity was significantly higher in heart
failure. Consistent with these results, we also found that H2O2
generation increased in heart failure compared to control (Fig.
1D). Furthermore, peroxynitrite production in cardiac tissue
homogenates was not significantly different in heart failure
compared to control (707 ± 228 vs. 1200 ± 408 arbitrary units/
mg protein).
Finally, the myocardial lipid peroxidation end products
malondialdehyde and 4-hydroxyalkenals were higher in heart
failure compared to control (7.9 ± 0.97 vs. 5.3 ± 0.67 nmol/mg
wet weight, P < 0.05).
Fig. 1. Sources of superoxide in normal and failing hearts. To determine the sources of superoxide, left ventricular tissue homogenates were freshly prepared from
normal (A; n = 7) and failing (B; n = 8) hearts and incubated with (A) the xanthine oxidase inhibitors allopurinol (Allo: 100 μmol/l) and oxypurinol (Oxy: 100 μmol/l),
(B) the NO synthase cofactor tetrahydrobioptrin (THB4: 10 μmol/l), (C) the NO synthase inhibitor L-nitro-arginine methyl ester (L-NAME: 1 μmol/l), and (D) the
NADPH oxidase inhibitor gp91ds-tat (50 μmol/l) for 30 min at 37 °C. At the end of incubation period, untreated controls and treated samples (20 ml) were used to detect
superoxide by lucigenin (5-μmol/l) chemiluminescence assay. Additionally, superoxide dismutase (SOD) activity (C) and H2O2 levels (D) were measured in normal
(n = 7) and failing (n = 8) hearts. *P < 0.05 vs. normal. #P < 0.05 vs. heart failure.
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activity
Concentration of reduced and oxidized glutathione and
glutathione reductase activity is shown in Fig. 2. OxidizedFig. 2. Reduced and oxidized glutathione levels and glutathione reductase activity
(GSSG; B), GSSG-to-total glutathione ratio (C) levels and glutathione reductase activ
*P < 0.05 vs. normal.glutathione was significantly elevated in heart failure compared
to control (Fig. 2B). Ratio of GSSG-to-total glutathione was
also significantly increased (Fig. 2C). Additionally, we found
that the activity of glutathione reductase was significantly
elevated in heart failure as compared to control (Fig. 2D).in the myocardium. Total glutathione (GSH+GSSG; A), oxidized glutathione
ity were measured in normal (n = 7) and failing (n = 8) heart homogenates (D).
Fig. 4. qRT-PCR for NADPH oxidase, Nox-2 and Nox-4. Nox-4 (A) and Nox-2
(B) mRNA levels were measured by qRT-PCR.
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NADPH oxidase can utilize both NADPH and NADH as
cosubstrates to generate O2
−. In failing heart tissue, NADH was
approximately 46% lower, while NADPH was approximately
100% higher (Fig. 3A). NADP+ levels were unchanged in
failing (7.5 ± 3.7 nmol/g) vs. normal (6.4 ± 2.6 nmol/g) hearts.
Total NADP++NADPH was increased in failing (22.9 ±
1.4 nmol/g) compared to normal (13.9 ± 1.8 nmol/g) hearts.
3.5. Enhancement of O2
− production by NADPH
The effects of NADPH supplementation on O2
− production in
failing heart tissue are shown in Fig. 3B. To determine the role
of NADPH in regulating NADPH oxidase activity, normal and
heart failure samples were incubated with NADPH (1–
1000 μM) and O2
− generation was detected by lucigenin
chemiluminescence assay. NADPH markedly stimulated O2
−
production in failing, but not in normal hearts, in a dose-
dependent manner (Fig. 3C). We also tested the effects of
NADH supplementation on O2
− production. Surprisingly, we
found that NADH (100 μM) increased O2
− production in tissue
from normal heart (419 ± 102 vs. 3303 ± 1305 arbitrary units/
mg protein, P < 0.05), but not from failing heart (1338 ± 420 vs.
1759 ± 1200 arbitrary units/mg protein, N.S.).
3.6. Gene and protein expression of Nox-2 and Nox-4
Figs. 4A and B show that Nox-4 and Nox-2 gene expression
was not significantly different in failing compared to normal
hearts. Nox-4 protein expression was not significantly different,
while Nox-2 protein expression was downregulated in failing
compared to normal hearts (Figs. 5A and B). Immunoprecip-
itation of p67phox indicates that a complex of p67phox and Nox-2Fig. 3. NADPH and NADH levels, and NADPH oxidase activity in the myocardium.
8) heart homogenates by HPLC. To determine the activity of NADPH oxidase, left ve
were incubated with NADPH (50 μmol/l) for 30 min at 37 °C. *P < 0.05 vs. norma
oxidase activity in myocardial homogenates from normal and failing hearts is showis present in normal and failing hearts (Fig. 5C), with no
significant difference between the two conditions. However, the
relative fraction of Nox-2 bound to p67phox, calculated as the
ratio of the immunoprecipitated Nox-2-p67phox complex to
Nox-2 prior to immunoprecipitation was increased in failing
(1.64 ± 0.19) as compared to normal (0.87 ± 0.02) hearts,
indicating activation of NADPH oxidase.
3.7. Activity and expression of G6PD
The pentose phosphate pathway is a major source of
NADPH in most cells, including cardiac myocytes. Hence,
we measured activity and expression of G6PD, the rate limitingNADPH and NADH levels were measured in the normal (n = 7) and failing (n =
ntricular tissue homogenates from normal (A; n = 7) and failing (B; n = 8) hearts
l. #P < 0.05 vs 1 μM. A dose–response curve of NADPH-stimulated NADPH
n in panel C.
Fig. 5. Western blot analysis for NADPH oxidase, Nox-2 and Nox-4. Nox-4 and Nox-2 protein by Western blot. Representative immunoblot bands (A) and summary
data (B) for Nox-4 and Nox-2 are shown. Lysates (1 mg of protein) prepared from myocardial tissue were immunoprecipitated with pre-immune serum (Pre) or
polyclonal anti-p67phox antibody (IP) and then immunoblotted with monoclonal anti-Nox-2 antibody (C). All input lanes contained 35 μg of total protein lysate
obtained prior to immunoprecipitation. n = 7 for normal and n = 8 for heart failure. *P < 0.05 vs. normal.
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pathway. G6PD activity was elevated by 1.5-fold in failing
compared to normal hearts (Fig. 6A). Consistent with this
finding, the concentration 6-phosphogluconate, an intermediate
product of the pentose phosphate pathway, was significantly
elevated in heart failure (Fig. 6B). Furthermore, G6PD gene
(Fig. 6C) and protein expression (Fig. 6D) were significantly
higher in failing heart tissue.
3.8. G6PD and O2
− production
To investigate whether increased pentose phosphate pathway
activity supplies NADPH to NADPH oxidase for sustained O2
−
generation in heart failure, we determined the effects of 6-Fig. 6. 6-Phospho-gluconate levels and glucose-6-phosphate dehydrogenase expressi
and protein expression of glucose-6-phosphate dehydrogenase (G6PD, B–D) in norm
are also shown (E). *P < 0.05 vs. normal.aminonicotinamide, an irreversible inhibitor of G6PD, on O2
−
generation. As shown in Fig. 7, incubation of the heart
homogenates with 6-aminonicotinamide did not affect O2
−
formation in normal myocardium, but almost completely
abolished it in the failing myocardium. 6-Aminonicotinamide
inhibited G6PD activity by 85.0 ± 5.6% as compared to
untreated control in normal and failing heart myocardial
homogenates.
4. Discussion
Previous studies have provided substantial evidence that
NADPH oxidase and uncoupled constitutive NOS are important
sources of O2
− in the failing heart [7,8,10,31]. These enzymeson and activity. 6-Phospho-gluconate (6PG; A) concentration and activity, gene
al (n = 7) and failing (n = 8) hearts. Representative immunoblot bands of G6PD
Fig. 7. Superoxide generation and glucose-6-phosphate dehydrogenase activity.
Left ventricular tissue homogenates from normal and failing hearts were
incubated for 30 min at 37 °C with or without 6-aminonicotinamide (6AN;
5 mmol/l), an inhibitor of glucose-6-phosphate dehydrogenase (G6PD). n = 7
for normal and n = 8 for heart failure. *P < 0.05 vs. normal.
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and it remains to be established whether, under pathological
conditions, they are driven by biochemical processes supplying
reducing equivalents. The present findings indicate that heart
failure causes upregulation and hyperactivity of myocardial
G6PD, and strongly suggest that the pentose phosphate pathway
enhances cytosolic NADPH availability, thus fueling O2
−
production by NADPH oxidase and uncoupled NO synthase.
Since glucose utilization is higher in the failing heart [12], our
study determined a novel mechanistic link between altered
energy substrate metabolism, NADP reduction, and oxidative
stress.
Cardiac oxidative stress plays a major role in the patho-
physiology of heart failure. ROS cause diastolic dysfunction by
impairing calcium-induced calcium release [32], decrease force
generation without altering calcium sensitivity of myofilaments
[33], and can activate metalloproteinases [34], thus triggering
ventricular remodeling.
In accord with prior findings in human and experimental
heart failure [7,8,31], we found elevated basal levels of O2
−
generation in myocardial tissue from dogs with pacing-induced
heart failure, compared to normal hearts. The detection of
increased oxidized glutathione and of lipoperoxidation end
products further supports the presence of a state of oxidative
stress in failing hearts. Therefore, the next step was to identify
the enzymes responsible for O2
− generation. Under our
experimental conditions, a major role was clearly played by
NADPH oxidase, since its specific inhibitor gp91ds-tat almost
completely abolished O2
− production in failing heart tissue. This
finding is in evident accord with a previous study performed by
Heymes et al. in homogenates of human failing heart [7].
Angiotensin II, noradrenaline, TNFα, and increased wall stress,
all of which are known to play a role in the pathology of heart
failure, activate NADPH oxidase. In fact, although we found
that gene and protein expression of the NADPH subunit Nox-4
and Nox-2 was not increased, it is known that translocation of
p47phox in cardiomyocytes from cytoplasm to plasma mem-
brane in failing human hearts activates Nox-2 and O2
−
production [7]. We have directly assessed the activation state
of the NADPH oxidase by determining complex of NADPH
oxidase subunits. Unfortunately, we could not find an antibodybinding to canine p47phox, but we could detect the p67phox-Nox-
2 interaction using a coimmunoprecipitation approach. We
found a significant increase in the complex between Nox-2 and
p67phox in normal vs. failing heart. This finding supports a
higher activation state of NADPH oxidase in the failing heart,
which has been already documented by other investigators
[7,8]. On the other hand, the NO synthase cofactor tetrahy-
drobiopterin or the competitive inhibitor L-NAME reduced O2
−
levels by approximately 65% and 77%, respectively, which
indirectly indicated the presence of uncoupled NO synthase
generating O2
− in the failing heart. The mechanisms of NOS
uncoupling could be very complex in a multifactorial disease
such as heart failure and not necessarily limited to tetrahy-
drobiopterin availability. For instance, it has been shown that
the association between heat shock protein 90 and eNOS limits
eNOS uncoupling even in normal hearts [35] and this
mechanism could be altered in the failing heart. Although we
cannot exclude that tetrahydrobiopetrin itself scavenged part of
O2
− in our tissue preparations, an important role for uncoupled
NOS is supported by the effect of L-NAME. Finally, O2
−
generation was reduced, albeit not significantly, by the xanthine
oxidase inhibitors allopurinol and oxypurinol. Although our
assay was not designed to precisely quantify the relative
contribution of different O2
− generating enzymes, these data
indicate that NADPH oxidase and uncoupled NOS played an
important role. Interestingly, the addition of NADPH further
enhanced O2
− production in a dose-dependent manner, suggest-
ing that NADPH oxidase activity uses NADPH as an electron
donor in the failing heart. This has important implications when
we consider that endogenous NADPH concentration was
increased by almost two-fold in heart failure.
What is the molecular basis for such a high level of NADPH
in failing hearts? Previous studies from our group and others
showed that pentose phosphate pathway-derived NADPH is a
major cosubstrate for NADPH oxidase [16,17]. Since glucose
utilization is higher in the failing heart [12,13], we hypothesized
that an increased amount of this energy substrate could be
channeled through the oxidative branch of the pentose
phosphate pathway, which is a major source of NADPH in
most cell types, including cardiac myocytes [36–38]. Compared
to control, expression and activity G6PD were found indeed
markedly elevated in the failing heart. This was consistent with
a more than doubled concentration of 6-phosphogluconate, the
product of the second reaction catalyzed along the pentose
phosphate pathway. G6PD expression and activity can be
stimulated by a large number of factors, only partially known,
while heart failure is characterized by an enormous number of
biochemical/molecular alterations. Although our data do not
provide mechanisms for G6PD upregulation, it should be
considered that elevated levels of O2
− and H2O2, per se, could
directly induce G6PD expression [39], and increased levels of
GSSG could activate G6PD [40].
When G6PD was inhibited, O2
− dropped to levels found in
normal hearts, indicating that the continuous supply of NADPH
from the pentose phosphate pathway was necessary to drive O2
−
generation. We cannot exclude an important contribution of
mitochondrial respiratory chain complexes or other enzymes to
348 S.A. Gupte et al. / Journal of Molecular and Cellular Cardiology 41 (2006) 340–349the generation of O2
− in vivo; however, taken together, our data
provide compelling evidence that failing heart tissue maintains
elevated levels of NADPH and has the molecular machinery
capable of enhancing glucose flux through the pentose
phosphate pathway, thus supplying large amounts of NADPH
that drive O2
− production. Interestingly, the increased availabil-
ity of NADPH in failing hearts appeared to have a more
dominant effect on promoting superoxide production compared
to its antioxidant metabolic effect of maintaining high levels of
reduced glutathione. A possible explanation is that, while in
normal hearts G6PD-derived NADPH is critical to preserve
cytosolic antioxidant redox systems such as GSH, [37,38] in the
presence of pathologically enhanced superoxide-generating
systems sharing the same type of electron donor, the NADPH
oxidase has a greater affinity for the available electron donor.
Consistent with this interpretation, other authors have recently
reported that, in a pathological condition induced by angioten-
sin infusion, G6PD deficiency limits the deleterious effects of
vascular superoxide production possibly by reducing the
availability of the substrate for NADPH oxidase [16].
In severe heart failure, cardiac oxidation of free fatty acid is
impaired, leading to augmented uptake and oxidation of the
alternative substrate glucose. However, other authors and us
previously found molecular alterations suggestive of a de-
pressed, rather than increased, glycolytic pathway [14,15]. This
is part of the global mitochondrial impairment that characterizes
heart failure [11]. It is possible, therefore, that a larger fraction
of glucose enters the upregulated pentose phosphate pathway.
In conclusion, our study provides evidence for elevated
NADPH in the failing heart due to G6PD upregulation. This
biochemical alteration drives superoxide production by
NADPH oxidase and uncoupled NO synthase. Thus, the flux
of glucose metabolism through the pentose phosphate pathway
may be playing an important role in fueling the oxidative stress
seen in heart failure.
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